Mesoblast MESO
NASDAQ MESO
$17.32 +0.18 (+1.05%)
At close: Sep 4, 2026 · 4:00 PM EDT

Mesoblast (MESO) Non-Current Deffered Revenue (2015 - 2026)

Mesoblast (MESO) posted Non-Current Deffered Revenue of $2.5 million for Q4 2025, little changed sequentially from $2.5 million in Q2 2025, and little changed YoY from $2.5 million in Q4 2024.

Analysis

Mesoblast (MESO) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends

Mesoblast has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $2.5 million in Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.5 million, changed 0.0% from the prior year.
  • Non-Current Deffered Revenue was little changed at $2.5 million in Q4 2025 per MESO's latest filing, from $2.5 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $91.6 million in Q4 2022 and troughed at $2.5 million in Q1 2021.
  • A 5-year average of $8.4 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue surged 3564.68% in 2022, then tumbled 97.27% in 2023.
  • Over 5 years, Non-Current Deffered Revenue stood at $2.5 million in 2021, then soared by 3564.68% to $91.6 million in 2022, then sank by 97.27% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.5 million, and $2.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Mesoblast 2.24 Bn 2.14 Bn - 2.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.50 Mn
Dec 31, 2025 2.50 Mn
Jun 30, 2025 2.50 Mn
Dec 31, 2024 2.50 Mn
Jun 30, 2024 2.50 Mn
Dec 31, 2023 2.50 Mn
Jun 30, 2023 2.50 Mn
Mar 31, 2023 2.50 Mn
Dec 31, 2022 2.50 Mn
Sep 30, 2022 2.50 Mn
Jun 30, 2022 2.50 Mn
Mar 31, 2022 2.50 Mn
Dec 31, 2021 2.50 Mn
Sep 30, 2021 2.50 Mn
Jun 30, 2021 2.50 Mn
Mar 31, 2021 2.50 Mn
Dec 31, 2020 2.50 Mn
Sep 30, 2020 2.50 Mn
Jun 30, 2020 2.50 Mn
Mar 31, 2020 2.50 Mn